

# To assess the impact of Target Inhalation Mode (TIM) aerosol delivery on the treatment time with nebulised antibiotic therapy in children with Cystic Fibrosis

**Submission date**

14/03/2011

**Recruitment status**

No longer recruiting

**Registration date**

07/04/2011

**Overall study status**

Completed

**Last Edited**

17/01/2012

**Condition category**

Nutritional, Metabolic, Endocrine

☐ Prospectively registered

☐ Protocol

☐ Statistical analysis plan

☒ Results

☐ Individual participant data

**Plain English summary of protocol**

Not provided at time of registration

## Contact information

**Type(s)**

Scientific

**Contact name**

Mrs Pamela McCormack

**Contact details**

Alder Hey Children's Hospital

Eaton Rd

Liverpool

United Kingdom

L12 2AP

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

09-02-RE

# Study information

## Scientific Title

A pilot randomised controlled trial to assess the impact of Target Inhalation Mode (TIM) aerosol delivery on the treatment time with nebulised antibiotic therapy in children with Cystic Fibrosis

## Acronym

TIM CF

## Study objectives

With an Adaptive Aerosol Delivery (AAD) device, use of target inhalation mode (TIM) will reduce the length of treatment times for inhalation when compared with standard tidal breathing mode.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Liverpool paediatric ethics committee and date of approval was 25/05/2009

## Study design

Pilot randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Cystic Fibrosis

## Interventions

Target inhalation mode vs tidal breathing mode for delivering aerosolised antibiotic through an adaptive aerosol delivery device

## Intervention Type

Other

**Phase**

Not Applicable

**Primary outcome measure**

Treatment time (seconds)

**Secondary outcome measures**

1. % Adherence to treatment
2. Pseudomonas growth (number of colony forming units on respiratory culture)
3. Pulmonary function (FEV1 and forced vital capacity (FVC), percent predicted for age, sex and height)
4. Adverse events (e.g. wheeze, or increase in wheeze or change in wheeze pattern)
5. Patient withdrawal
6. Patient reported outcomes using Challenges of Living with Cystic Fibrosis (CLCF) questionnaire

**Overall study start date**

01/06/2009

**Completion date**

31/05/2010

## **Eligibility**

**Key inclusion criteria**

1. Patients with a valid diagnosis (sweat chloride > 60 or two CF causing gene mutations)
2. Airway infection with Pseudomonas aeruginosa requiring long term nebulised Colistin therapy
3. Established on standard Tidal Breathing Mode of delivery using AAD device for Colistin therapy
4. Ability to comprehend use of the TIM device and follow instruction
5. Aged more than or equal to 5 years and able to perform lung function
6. No recent (> 6 weeks) exacerbation of chest condition as defined by
  - 6.1. A deterioration forced expiratory volume in one second (FEV1) more than or equal to 10% from previously recorded value
  - 6.2. Cough
  - 6.3. Change in sputum production

**Participant type(s)**

Patient

**Age group**

Child

**Sex**

Both

**Target number of participants**

20

**Key exclusion criteria**

1. Patient with first growth of *Pseudomonas aeruginosa* requiring short term (3 months) colistin therapy
2. Patients prescribed alternate month TOBI and Colistin nebulised therapy
3. Patients with an acute exacerbation respiratory symptoms

**Date of first enrolment**

01/06/2009

**Date of final enrolment**

31/05/2010

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

Alder Hey Children's Hospital

Liverpool

United Kingdom

L12 2AP

## Sponsor information

**Organisation**

Alder Hey Children's NHS Foundation Trust (UK)

**Sponsor details**

Eaton Rd

Liverpool

England

United Kingdom

L12 2AP

**Sponsor type**

Hospital/treatment centre

**ROR**

<https://ror.org/00p18zw56>

# Funder(s)

## Funder type

Government

## Funder Name

Alder Hey Children's Foundation Trust Endowment Fund (UK)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2011		Yes	No